Scholarlink

Background <p>Mutations in <i>TP53</i> are associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). In this study, we investigated the relationship between <i>TP53</i> mutations and lipid metabolism abnormalities caused by sterol O-acyltransferase 1 (SOAT1). We hypothesized that SOAT1 inhibitors would show high efficacy in patients with PDAC with <i>TP53</i> mutations.</p> Materials and Methods <p>We performed SOAT1 immunohistochemistry staining of PDAC clinical tissue samples with next-generation sequencing-based comprehensive genomic profiling. We also confirmed the inhibitory effect of SOAT1 using siRNA and avasimibe in vitro and in vivo on pancreatic cancer cells of various <i>TP53</i> states. We confirmed the mechanism using RNA sequencing analysis.</p> Results <p>We identified a positive correlation between <i>TP53</i> mutations and high SOAT1 expression. Notably, the prognosis of PDAC was worse in the presence of <i>TP53</i> mutation than in the presence of wild-type <i>TP53</i>. Cell proliferation was more strongly suppressed in mutant p53 cells than in wild-type p53 and p53 null cells. Furthermore, we demonstrated that these observations were due to the presence of mutant p53 by adjusting the background via the introduction of mutant <i>TP53</i>. Antitumor efficacy resulting from SOAT1 inhibition was analyzed using RNA sequencing, and cell cycle suppression was observed only in mutant p53 cells.</p> Conclusions <p>Our results demonstrated that SOAT1 was upregulated in PDAC with <i>TP53</i> mutations and that SOAT1 inhibition was more effective in <i>TP53</i>-mutated PDAC. These findings would aid in the development of targeted therapeutic strategies against PDAC with <i>TP53</i> mutations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations

  • 期刊论文

  • 发表日期：

    2025年5月30日

查看全文
  • Ryosuke Maki,
  • Yoshifumi Iwagami,
  • Shogo Kobayashi,
  • Kazuki Sasaki,
  • Daisaku Yamada,
  • Yoshito Tomimaru,
  • Daisuke Sakai,
  • Takehiro Noda,
  • Tadafumi Asaoka,
  • Hidenori Takahashi,
  • Taroh Satoh,
  • Junzo Shimizu,
  • Yuichiro Doki,
  • Hidetoshi Eguchi

摘要

Background

Mutations in TP53 are associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). In this study, we investigated the relationship between TP53 mutations and lipid metabolism abnormalities caused by sterol O-acyltransferase 1 (SOAT1). We hypothesized that SOAT1 inhibitors would show high efficacy in patients with PDAC with TP53 mutations.

Materials and Methods

We performed SOAT1 immunohistochemistry staining of PDAC clinical tissue samples with next-generation sequencing-based comprehensive genomic profiling. We also confirmed the inhibitory effect of SOAT1 using siRNA and avasimibe in vitro and in vivo on pancreatic cancer cells of various TP53 states. We confirmed the mechanism using RNA sequencing analysis.

Results

We identified a positive correlation between TP53 mutations and high SOAT1 expression. Notably, the prognosis of PDAC was worse in the presence of TP53 mutation than in the presence of wild-type TP53. Cell proliferation was more strongly suppressed in mutant p53 cells than in wild-type p53 and p53 null cells. Furthermore, we demonstrated that these observations were due to the presence of mutant p53 by adjusting the background via the introduction of mutant TP53. Antitumor efficacy resulting from SOAT1 inhibition was analyzed using RNA sequencing, and cell cycle suppression was observed only in mutant p53 cells.

Conclusions

Our results demonstrated that SOAT1 was upregulated in PDAC with TP53 mutations and that SOAT1 inhibition was more effective in TP53-mutated PDAC. These findings would aid in the development of targeted therapeutic strategies against PDAC with TP53 mutations.